BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31071715)

  • 1. Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.
    de Mestier L; Walter T; Evrard C; de Boissieu P; Hentic O; Cros J; Tougeron D; Lombard-Bohas C; Rebours V; Hammel P; Ruszniewski P
    Neuroendocrinology; 2020; 110(1-2):83-91. PubMed ID: 31071715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
    Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
    Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
    de Mestier L; Walter T; Brixi H; Evrard C; Legoux JL; de Boissieu P; Hentic O; Cros J; Hammel P; Tougeron D; Lombard-Bohas C; Rebours V; Ruszniewski P; Cadiot G
    Neuroendocrinology; 2019; 108(4):343-353. PubMed ID: 30759445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
    Papaxoinis G; Kordatou Z; McCallum L; Nasralla M; Lamarca A; Backen A; Nonaka D; Mansoor W
    Neuroendocrinology; 2020; 110(5):413-421. PubMed ID: 31437838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake.
    Ostwal V; Basu S; Bhargava P; Shah M; Parghane RV; Srinivas S; Chaudhari V; Bhandare MS; Shrikhande SV; Ramaswamy A
    Neuroendocrinology; 2021; 111(10):998-1004. PubMed ID: 33017827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
    Squires MH; Worth PJ; Konda B; Shah MH; Dillhoff ME; Abdel-Misih S; Norton JA; Visser BC; Dua M; Pawlik TM; Schmidt CR; Poultsides G; Cloyd JM
    Pancreas; 2020 Mar; 49(3):355-360. PubMed ID: 32132509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.
    Spada F; Maisonneuve P; Fumagalli C; Marconcini R; Gelsomino F; Antonuzzo L; Campana D; Puliafito I; Rossi G; Faviana P; Messerini L; Barberis M; Fazio N
    Endocrine; 2021 Apr; 72(1):268-278. PubMed ID: 32700133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
    Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
    Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Ki-67 Index to Predict Treatment Response to the Capecitabine/Temozolomide Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study.
    Wang W; Zhang Y; Peng Y; Jin KZ; Li YL; Liang Y; Tan HY; Yu XJ; Zhou ZW; Chen J
    Neuroendocrinology; 2021; 111(8):752-763. PubMed ID: 32668427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
    Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
    Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
    Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
    Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.
    Chatzellis E; Angelousi A; Daskalakis K; Tsoli M; Alexandraki KI; Wachuła E; Meirovitz A; Maimon O; Grozinsky-Glasberg S; Gross D; Kos-Kudła B; Koumarianou A; Kaltsas G
    Neuroendocrinology; 2019; 109(4):333-345. PubMed ID: 31167197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
    Gao H; Dong J; Zhang W; Xu H; Ye L; Li H; Ni Q; Wang W; Liu L
    Endocr Pract; 2022 Mar; 28(3):292-297. PubMed ID: 34454077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
    Al-Toubah T; Morse B; Strosberg J
    Oncologist; 2020 Jan; 25(1):e48-e52. PubMed ID: 31455747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
    Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
    Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).
    Kunz PL; Graham NT; Catalano PJ; Nimeiri HS; Fisher GA; Longacre TA; Suarez CJ; Martin BA; Yao JC; Kulke MH; Hendifar AE; Shanks JC; Shah MH; Zalupski MM; Schmulbach EL; Reidy-Lagunes DL; Strosberg JR; O'Dwyer PJ; Benson AB
    J Clin Oncol; 2023 Mar; 41(7):1359-1369. PubMed ID: 36260828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
    Cros J; Hentic O; Rebours V; Zappa M; Gille N; Theou-Anton N; Vernerey D; Maire F; Lévy P; Bedossa P; Paradis V; Hammel P; Ruszniewski P; Couvelard A
    Endocr Relat Cancer; 2016 Aug; 23(8):625-33. PubMed ID: 27353036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
    Al-Toubah T; Morse B; Pelle E; Strosberg J
    Oncologist; 2021 Feb; 26(2):115-119. PubMed ID: 33225478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience.
    Douangprachanh S; Joo HJ; Park HM; Han N; Jang HY; Koh YH; Kim TH; Han SS; Park SJ; Lee WJ; Woo SM; Chun JW
    Korean J Intern Med; 2022 Nov; 37(6):1216-1222. PubMed ID: 36375489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms.
    Al-Toubah T; Pelle E; Valone T; Haider M; Strosberg JR
    J Natl Compr Canc Netw; 2021 Aug; 20(1):29-36. PubMed ID: 34433130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.